Summary The effects of expression of human c-myc and both mutated (T24) and normal forms of human Ha-ras-1 were studied in an aneuploid rat fibroblast line (208F). Mutated T24 Ha-ras was also studied in a near-diploid cell derived from early passage Chinese hamster lung fibroblasts (CHL). In contrast to the parental fibroblasts, cells expressing any of the human oncogenes engendered rapidly growing tumours in immune-suppressed animals. Blood-and lymph-borne metastases were observed from both ras-and mycexpressing cells. In general ras-expressing cells were more aggressive than those expressing myc. In the 208F background, expression of c-myc was associated with an incidence of mitosis similar to that in tumours expressing T24 Ha-ras, but incidence of single cell death by apoptosis was higher. Quantitatively, expression of human oncogene mRNA was constant during growth in vivo, and similar to that sometimes observed in human neoplasms. Of 9 endogenous proto-oncogenes, 7 showed no change in expression from the parental fibroblasts, but c-abl and c-fos were strongly expressed in all cells expressing human ras or myc. Thus these tumorigenic cells, although transfected with single human oncogenes, all expressed oncogenes with both nuclear-and membrane-associated products.
There is much evidence that cellular oncogenes of the ras and myc families play a role in carcinogenesis (reviewed by Klein & Klein, 1986; Weinberg, 1985) , but surprisingly little is known of their contribution to the pathology of established tumours, and in particular to features of malignancy such as growth by infiltration or metastasis. In human neuroblastomas, there is a suggestive but incomplete correlation between aggressive clinical course and amplification (with overexpression) of N-myc (Brodeur et al., 1984; Rosen et al., 1986) . High levels of ras expression occur frequently in primary human neoplasms of many types (Slamon et al., 1984; Spandidos & Agnantis, 1984; Spandidos & Kerr, 1984; De Bertoli et al., 1985; Spandidos et al., 1985b; Kurzrock et al., 1986) but there is no evidence that this is necessary or sufficient for maintenance of the malignant phenotype (Gallick et al., 1985; Williams et al., 1985) . Rodent fibroblasts in which expression of ras genes (with or without mutational activation) has been induced in vitro, do acquire metastatic ability, however, as judged by a pulmonary embolisation assay Thorgeirsson et al., 1985) . Moreover, the metastatic phenotype appears almost immediately on expression of the inserted ras genes (Bradley et al., 1986) . Ras-expressing cells develop a constellation of new features. Some of these could be expected to favour autonomous growth, such as the production of tumour growth factors (Ozanne et al., 1982; Anzano et al., 1985; Pragnell et al., 1985; Spandidos, 1985; Marshall et al., 1985) and release from pre-existing control by exogenous trophic stimuli (Kasid et al., 1985; Racker et al., 1985; Zahn & Goldfarb, 1986) , whilst some correlate strongly with invasive and metastatic ability, such as increased sialylation of surface glycoproteins (Collard et al., 1985) . Ras gene expression, however, is also associated with enhanced cellular capacity to act as a target for NK cytocidal activity (Johnson et al., 1985; Trimble et al., 1986) a feature likely to militate against successful metastasis (Nicolson & Poste, 1983; Hanna & Schneider, 1983) . Any relationship between ras expression and metastatic capacity is likely to be influenced in addition by as yet unknown cellular factors since ras expression appears to have little to do with metastatic potential in murine cell lines of melanoma (Kris et al., 1985) or epithelial origin . Even in fibroblasts there is evidence that the induction of metastatic potential by ras expression may be inhibited by products of other genes (Pozzatti et al., 1986) .
In this paper we observe the effect of human c-myc and Ha-ras-1 genes on early and late passage fibroblasts, inoculated subcutaneously into immune-suppressed mice. Expression of the oncogenes is ensured through their linkage to strong viral transcriptional enhancer elements (Spandidos & Wilkie, 1984; Spandidos, 1985) . In particular we ask whether the tumours containing these oncogenes differ in their growth properties at the site of inoculation or in their metastatic ability, whether the abilities to metastasise by lymphatic and haematogenous routes are conferred together, or independently of each other, and whether expression of endogenous proto-oncogenes is altered.
Materials and methods

Cell lines
All cell lines were maintained in Dulbecco's modification of minimum Eagle's medium (MEM), supplemented to 10% with new-born calf serum and penicillin and streptomycin. The genesis of the cell lines has been fully described elsewhere (Spandidos & Wilkie, 1984) . CHL cells derived from early passage hamster fibroblasts, whereas the 208F cell line originated from Fisher rat fibroblasts (Quade, 1979) and is aneuploid in karyotype. From the 208F cell line 3 derivative lines were obtained through insertion of mutated (T24) and non-mutated human Ha-ras-1 and human c-myc genes in high expression vectors, by the calcium phosphate transfection technique. A single derivative cell line from CHL fibroblasts was also studied, containing the mutated (T24) human Ha-ras-I gene (hereafter called simply T24 Haras). Each derivative line was expanded from a single clone. A satisfactory myc-expressing CHL transfectant has not been obtained. The plasmids used for transfection were pHOSTl, pHO6Nl and pMCGM1, containing the entire T24 Ha-ras gene (aph), conferring resistance to geneticin (G418), which was used in the initial selection of the lines.
Animals
Female CBA mice of around six weeks of age were rendered incompetent immunologically by thymectomy followed by whole-body radiation and treatment with cytosine arabinoside by a modification of the method of Steel et al. (1978) (Hay et al., 1985) . CHL, 208F, and the derivative myc and ras expressing lines were suspended in Dulbecco's PBS at a concentration of 1-2x 108 ml-1, and inoculated subcutaneously in volumes of 0.1 ml, either to the left groin or the mid-dorsal region around 4 weeks after whole body irradiation. The mice were observed for tumour development and killed at times dictated by the following criteria: tumours of over 1.0 cm diameter, obvious illness, or the passage of at least four weeks with no or slow tumour development. Although these criteria are somewhat divergent, they afforded a convenient way to gather tumours of widely differing behaviour: the rapidly growing tumours appeared within 1-2 weeks and were harvested within 1-3 weeks of injection, animals with slower growing tumours could be observed for longer, and the longest periods of observation were reserved for animals in which there was no evidence of tumour development.
At autopsy, portions of the tumour, and the lungs, heart, liver, kidneys, adrenals, retro-peritoneal lymph nodes, and axillary lymph nodes were fixed in 4% neutral buffered formaldehyde, and processed through paraffin for preparation of sections stained by haematoxylin and eosin, van (Chirgwin et al., 1979) . After repeated precipitation in ethanol, RNA was checked for integrity by observation of discrete ribosomal RNA bands on 1% agarose gels containing 6.8% formaldehyde (Maniatis et al., 1982) , and stained with ethidium bromide. For semiquantitative analysis of oncogene expression a spot hybridisation assay was employed (Spandidos et al., 1981) . RNA (5 , ug) was spotted on nitrocellulose filters and probed with oncogene DNA, labelled by nick translation with 32P-dCTP under the following hybridisation conditions: 50% formamide, 2 x SSPE, 5 x Denhardt's solution, 200 jg ml-1 sheared salmon DNA, 0.5% SDS at 40°C for 18-24h. After washing to stringencies specified in the text, the filters were exposed to Fuji-Rx film.
For quantitative estimation of Ha-ras and c-myc RNA, dots containing 1, 5 and lO jg of total cellular or tumour RNA were spotted, in triplicate, adjacent to serial dilutions, also in triplicate, of known quantities of Ha-ras or c-myc RNA, generated from the plasmids pSPHa-ras 2 and pMC64-10 using SP6 RNA polymerase. Filters were probed with nick translated T24 Ha-ras or c-myc sequences as described above. Following hybridisation RNA spots were cut from the nitrocellulose filter using a cork borer and the amount of hybridised probe determined by liquid scintillation. The mean value for each triplet of spots was calculated and a standard curve plotted using the values obtained for SP6-generated Ha-ras or c-myc RNA. The quantity of Ha-ras or c-myc RNA present in 1, 5 or 1O pg of total cellular or tumour RNA was determined by intrapolation on this standard curve. Values thus obtained for Ha-ras and c-myc RNA were corrected to compensate for the presence of noncoding sequences in the SP6 generated RNA. Such sequences account for approximately 50% of the Ha-ras RNA and 75% of the c-myc RNA. The resulting value was expressed as a percentage of total RNA or of poly A' RNA (using the assumption that 2% of total RNA is poly A' RNA).
Plasmids used for hybridisation probes and RNA calibration All probes were purified linear DNA sequences, isolated from their plasmid vectors by restriction enzyme cleavage and separation on low melting temperature I % agarose gels as described below. The ensuing list gives the designation of plasmids used for preparation of hybridisation probes, preceded by the gene sequence represented and followed in brackets by the restriction enzyme fragment selected.
Human Ha-ras-1: pT24-C3 (Sacl 2.9 kb); human c-myc: pMC41-Cl (EcoRI, Hind!!! 8.4kb); human Ki-ras-2: pSP3K (EcoRI, HindIll 0.64kb); mouse muscle actin: pAM91(PstI, 1.1 kb); human rDNA: pHR (EcoRI, 6.7kb) (details of these plasmids are given in Spandidos & Kerr, 1984 v-erb-B: pverb-B-DT (BamHl, 0.5kb) (from D. Tannahill, Edinburgh University).
The plasmids pSPH-ras 2 and pMC64-10 were constructed by insertion into the vector SP64 of (respectively) the 2.9 kb Sac! fragment of the human T24 Ha-ras gene (containing all four coding exons) or the 8.4kb EcoRI/HindIll fragment of the human c-myc gene (containing all three coding exons). Oncogene RNA was generated by incubation with SP6 polymerase (Melton et al., 1984) under the conditions recommended by the manufacturer (Bethesda Research Laboratories(BRL), Paisley, Scotland).
Immunoblotting
Monolayers of cultured cells were detached by incubation in phosphate buffered saline containing 0.02% EDTA, and lysed in 100mM sodium chloride, 10mM Tris pH 7.5, 0.1% SDS, 1% NP40. Portions of snap frozen tumour were treated similarly. Electrophoresis in 15% polyacrylamide gels, electrophoretic blotting on nitrocellulose, and immunostaining with Y13-259 (Furth et al., 1982) were conducted as previously described , but using an alkaline phosphatase-streptavidin system (Blu-gene, BRL) to detect the biotinylated second antibody.
Results
Pathology of 'primary' tumours A summary of the tumour development at the subcutaneous injection sites is given in Table I . Animals injected in groin and back showed similar features and are considered together.
CHL cells without human oncogenes never produced visible or palpable tumours, and on autopsy 5 weeks after inoculation no abnormality was detected at the injection site. 208F cells, without human oncogenes, although reputedly non-tumorigenic, consistently yielded small, slowly-growing nodules, not exceeding 5mm diameter even after 5 weeks. Histologically these were low grade fibrosarcomas, with few mitotic figures. There was conspicuous collagen deposition around and between the tumour cells, and mast cells of presumed host origin were plentiful within the tumours. No necrosis was observed within these tumours, but cells at the tumour edge appeared to be infiltrating between adjacent adipocytes ( Figure 1A ). CHL cells bearing the T24 Ha-ras gene yielded rapidly growing tumours in all animals, reaching diameters of over 1 cm within 2 weeks. The tumours infiltrated, and sometimes ulcerated, the overlying skin but were tethered to underlying connective tissue only rarely. Histologically these were aggressive fibrosarcomas with a high mitotic rate and little collagen between cells although nascent collagen bundles were identified on electron microscopy ( Figure 1B) . Zones of necrosis were conspicuous in the centre of the tumours but mast cells were not identified. Cells at the tumour periphery infiltrated around and within the striated muscle fibres of the panniculus carnosus, apparently destroying them ( Figure IC) . Infiltration into adjacent fat and around epidermal appendages was also evident, but a mantle of mononuclear cells of uncertain histogenesis was often observed running circumferentially around the deep margin of the tumour. Several tumours showed extensive infiltration by neutrophil polymorphs, and regression was obvious in a proportion harvested between 13 and 35 days. Histologically, such clearly regressing tumours consisted of masses of fat necrosis with heavy neutrophil polymorph infiltration ( Figure ID) . Despite this evidence of regression in some animals, the majority of tumour-bearing animals bore progressively enlarging tumours at the time of autopsy.
208F cells bearing T24 Ha-ras genes produced rapidly enlarging fibrosarcomas of similar morphology to the above ( Figure 2A ) and with a similar proportion showing regression. Similarly, 208F cells expressing the normal human Ha-ras-1 gene produced rapidly growing, potentially lethal tumours, although these showed less necrosis at similar size than the tumours bearing the mutated oncogenes. 208F cells bearing human c-myc also produced growing tumours, but in a significantly smaller proportion of animals than after injection of ras-bearing cells. In seven of the animals the tumours were aggressive fibrosarcomas ( Figure 2B ), but in the remaining six the morphology was intermediate between this and the indolent pattern of 208F cells alone. All these tumours were substantially larger than those produced by 208F cells alone, as observed at autopsy at closely similar times after inoculation. However, they grew less rapidly than the more aggressive variants, reached smaller diameters at the time of autopsy, and did not contain central necrotic areas.
Oncogene expression in aggressive fibrosarcomas Expression of c-myc, Ha-ras, and nine proto-oncogenes was assessed in examples of the aggressive fibrosarcomas, harvested within 2 weeks of inoculation (Table II and Figure  3) . In tumours bearing the mutated human T24 Ha-ras gene, Ha-ras transcripts were present at levels close to those in the originally injected cells. Thus, in both CHL and 208F cells containing the T24 Ha-ras gene, levels of transcript were estimated at around 0.8% of total cellular mRNA, between 20-and 53-fold greater than the untransfected parent cells. Figure 4 ). The immunoblots also confirmed that the cells bearing the normal human proto-oncogene expressed much more p2lras than the parental fibroblasts (in which p2lras was barely detectable by the methods used) and to at least as great a degree as the cells expressing the T24 Ha-ras gene. In contrast to these high levels of expression of the inserted human oncogenes, several other oncogenes tested (including src, erb-B, fJs, myb, int-2 and Ki-ras) showed low or barely detectable levels of expression in the aggressive tumours themselves, the cells transfected with human c-myc and Ha-ras prior to animal injection, and the parental untransfected cells (Figure 3) . Moderate expression of c-sis was observed in both parental fibroblast lines and their rasand myc-expressing derivatives. In contrast, substantially elevated expression of abl and fos was noted in the transfected cells relative to both their parental untransfected fibroblasts, regardless of whether the transfected gene was human c-myc or T24 Ha-ras.
Metastases from ras-and myc-expressing tumours In around one third of animals in which tumours expressing T24 Ha-ras grew at the inoculation site, there was evidence of either blood-or lymph-borne metastasis (Table I ). Bloodborne metastases were all observed within 14 days, as were the majority of the lymphatic metastases. Of the animals injected with cells expressing normal human Ha-ras-1, two developed metastases, both in lymph nodes, but these also were detected within 14 days of injection. Of the 13 animals in which myc-expressing cells produced a progressively growing 'primary' tumour, two showed metastases, one by lymphatics, the other (presumably haematogenous ) in the lung. In one of these animals the 'primary' tumour showed the aggressive type of histology. The total number of animals with metastatic tumours was small, and the lower overall yield with myc-expressing tumours, although suggestive, is not statistically significant. Nonetheless, the metastases in both animals with myc-expressing secondary tumours were detected substantially later than all the metastases from rasexpressing tumours by the corresponding route. If metastases detected by two weeks only are considered, the difference in incidence between T24 Ha-ras and c-myc expressing tumours is significant (Table I) .
Morphologically, blood-borne metastases from the rasbearing tumours had similar morphology, regardless of whether the original transfected cell was of CHL or 208F type. Such metastases were found only in the lung, and clearly emanated from small branches of the pulmonary artery, filled with tumour cells (Figure 5A ). Lymphatic metastases were found in the para-iliac and para-aortic nodes in animals injected subcutaneously in the groin, and in the axillary nodes in animals injected in the back. The affected lymph nodes were usually entirely occupied by tumour cells, but in some there was evidence of partial colonisation, commencing in the subcapsular sinus ( Figure SB) .
In the single example of lymphatic metastasis from mycexpressing 208F cells, the histology was similar to that in the ras-expressing tumours, but the pulmonary metastasis was unusual: a single small intra-pulmonary tumour nodule was associated with malignant pleural effusion. (0) and apoptosis (0) in the viable portions of tumours expressing normal human Ha-ras-1, T24 Ha-ras, and c-myc, or in the nodules engendered by the parental 208F fibroblasts. All tissues were harvested between 9 and 21 days after injection, with the exception of the 208F nodules marked *-, O-, which were harvested at 33 days. For each animal the mean incidence of mitosis and apoptosis in 10 high power fields was measured. There are significant differences in incidence of mitosis between Ha-ras-l and both T24 Ha-ras and c-myc tumours (P<0.001; Student's t test). Significant differences in incidence of apoptosis exist between T24 Ha-ras and both Ha-ras-I and c-myc tumours (P<0.001) and also between Ha-ras-l and c-myc tumours (P<0.02).
cells or extravasation of red cells was conspicuous. In the small, indolent fibrosarcomas engendered by 208F cells alone mitotic rates were consistently low. In animals killed at 33 days single cell loss by apoptosis was also infrequent, but larger numbers of apoptotic cells were observed in one animal killed at 14 days. The oncogene-expressing tumours were studied only at 9-14 days after injection. 208F cells bearing T24 Ha-ras produced tumours with high mitotic rates (-10 fold more than parental 208F cells at the same time after injection) but low apoptotic rates. Tumours expressing the normal Ha-ras-l gene had lower mitotic rates, but apoptosis was more frequent. In the more aggressive c-myc expressing tumours harvested at around the same time after injection both mitotic and apoptotic rates were high.
Discussion
Several groups have reported the ability of ras genes (with and without mutation) to confer metastatic activity on fibroblasts (Spandidos & Wilkie, 1984; Thorgeirsson et al., 1985; Muschel et al., 1985; Bradley et al., 1986; Liotta, 1986) although the assays used have focussed almost exclusively on haematogenous tumour spread. Here we present evidence that high expression of the mutated T24 Ha-ras-1 gene confers aggressive properties, to an indistinguishable degree, on both early and late passage fibroblasts. High expression of the normal human Ha-ras-I proto-oncogene is also associated with rapidly growing tumours capable of metastasis. In contrast, high expression of myc, in late passage fibroblasts, is associated with tumours which grow less aggressively as measured in terms of primary 'take' rate, growth rate, histology at the injection site, and the speed of ____ji I ---development and proportion of animals affected by metastasis. We have found no evidence that blood-borne and lymphatic metastases are differentially affected by myc or ras genes. Clearly, this study carries the usual strictures on interpretation of the metastatic process (Mareel & van Roy, 1986) . Thus, although we attempted to inoculate cells into the subcutaneous tissue spaces, we cannot exclude the possibility that some cells entered damaged veins or lymphatics at the time of injection, rather than entering these in the course of tumour growth. It has frequently been argued, however, that even should such direct implantation into vessels have occurred, the development of tumours at distant sites still depends upon many of the factors essential for bona fide metastasis of true primary tumours (Nicolson & Poste, 1983; Liotta, 1986) .
In experiments of this design it is not possible to be completely certain that expression of the inserted human oncogene is solely responsible for the malignant phenotype observed. One trivial explanation would be that the different types of growth behaviour observed are entirely coincidental features of the particular cell clones studied. This seems improbable, as high expression of T24 Ha-ras engenders tumours with rather similar behaviour in entirely different lines -CHL and 208F in this study, and fibroblasts of other origins elsewhere Bradley et al., 1986; Pozzatti et al., 1986) . A second possibility is that the new cell behaviour appearing after transfection is due to the viral enhancers in the transfected plasmids rather than the oncogenes themselves. The role of enhancers in carcinogenesis has been emphasised (Chichutek & Duesberg, 1986; Lang & Spandidos, 1986 (Spandidos & Wilkie, 1984) . A third and less readily dismissed possibility is that the aggressive features observed are due to genetic changes related to the oncogene expression only in a permissive sense, but occuring during the process of selection for growth in vitro and in vivo. Substantial cell selection necessarily occurs between the time of transfection and animal inoculation. There is also good evidence that growth of inoculated cells in vivo can be associated with major changes in phenotype (Nicolson & Poste, 1983) and oncogene arrangement (Winter & Perucho, 1986) . Karyotype analysis has shown that the ras-expressing CHL cells show several chromosomal changes as compared to the parent, untransfected cells which have a normal, diploid karyotype (Spandidos et al., 1985a) . The 208F karyotype is also hyperdiploid. However, rasexpressing fibroblasts have been found to metastasise without showing obvious progressive karyotypic changes in vivo , and we have confirmed here that levels of expression of both the transfected oncogenes and several proto-oncogenes remain remarkably constant during the growth of aggressive fibrosarcomas in vivo.
It is of interest to compare the level of expression of myc and ras genes in the transfected fibroblasts used here with that in authentic human tumours. Although absolute values of oncogene mRNA are seldom reported for the cells of human tumours, the ratio of expression in neoplastic versus control tissue is well documented. Thus myc expression may show elevation in fresh leukaemic cells of 10-50 fold over that in resting lymphocytes (Rothberg et al., 1984) and of 17 fold between the most and least expressing examples of prostatic adenocarcinoma (Fleming et al., 1986) . Even in the course of non-neoplastic cell activation, myc expression may rise up to 40 fold (Kelly et al., 1983) . The myc expression in our transfected fibroblasts of around 20 fold above the parental level is thus well within this range. Increased expression of ras, although usually at more moderate levels in both neoplastic and normal cells (Goyette et reported in benign colonic neoplasms as high as 30 fold more than normal epithelium (Spandidos & Kerr, 1984 ).
An unexpected finding in this study was the observation that c-abl and c-fos were highly expressed in fibroblasts transfected with recombinant plasmids carrying the T24 Ha-ras or c-myc genes. To our knowledge this is the first demonstration of alteration in expression of endogenous c-oncs after insertion of extraneous oncogenes in high expression vectors although accumulation of c-fos protein has been induced in 3T3 fibroblasts by microinjection of p2lras (Stacey et al., 1987) . One implication of this observation is that all the tumorigenic cell lines investigated here express oncogenes of both nuclear-and membrane-associated groups (fos or myc and abl or ras). Hence the generalisation that tumorigenicity requires co-activation of complementary oncogene groups (Land et al., 1983; Ruley, 1983; Weinberg, 1985) may apply even to cells transfected with single extraneous oncogenes. We have no direct evidence on the nature of the relationship between expression of the transfected myc and ras genes and the activation of the endogenous c-abl and c-fos. Enhanced expression of receptors for a or ,B TGF, and increased release of TGFs, have been recorded in ras and myc expressing cells however (Ozanne et al., 1982; Heldin & Westermark, 1984; Anzano et al., 1985; Pragnell et al., 1985; Spandidos, 1985) , and activation of c-fos is known to be dependent upon a wide spectrum of growth factors (Kruijer et al., 1985; Colletta et al., 1986 ). It appears unlikely that this activation of c-abt and c-fos could be solely responsible for the aggressive growth of the transfected lines, however, since levels of expression in the transfected cells, were similar for both ras and myc bearing transfctants, despite the differences in behaviour of these cells in vivo.
One outstanding difference between myc-and rasexpressing tumours of otherwise similar histology was the 'disparity in their rates and modes of cell death. It has long been appreciated that two contrasting modes of death can be observed in tissues: necrosis, characterised by cell swelling and rupture, and apoptosis, in which single cells shrink and fragment, but retain intact membranes, and are subject to phagocytosis by their viable neighbours (Kerr et al., 1972; Wyllie et al., 1980) . Zones of necrosis appeared in both ras-and myc-expressing fibrosarcomas as they do in most malignant tumours of man and animals. Although there is much current interest in the cause of this, and a range of explanations is offered, including lack of oxygen and nutrient (Rotin et al., 1986) , inadequate production of angiogenic factors (Denekamp & Hobson, 1982; Folkman, 1986) , or the effect of tumour necrosis factors (Old, 1985; Klostergaard et al., 1986) , it is clear that in our material, necrosis of this type appeared in the more aggressive fibrosarcomas rather than the small, indolent ones, and bore no correlation with other indices of aggression. In contrast, cell loss by apoptosis within the viable portion of the tumour, which is also a feature of most growing human and animal tumours (Wyllie, 1985) , was much commoner (relative to mitosis) in mycexpressing tumours as compared with the generally more aggressive tumours expressing T24 Ha-ras. The tumours expressing normal human Ha-ras-1 showed an intermediate pattern. It has long been suspected that the high cell loss rates observed in many growing animal and human tumours may represent an intrinsically regulated process (Kerr et al., 1972; Wyllie et al., 1980) . We do not know what factors within these tumours may be responsible, but it is interesting to speculate that one of the results of expression of the mutated Ha-ras oncogene may be to override the spontaneous deletion of cells within tumour populations, and so perhaps conserve cells with progressive deviation from normality.
In conclusion, high levels of expression of ras and myc oncogenes in rodent fibroblasts are associated with a range of new cellular features including aggressive growth, characteristic patterns of cell turnover, and transcriptional activation of endogenous proto-oncogenes. Several of these features have no obvious immediate relationship with the known sites and modes of action of ras p21 products (Wakelam et al., 1986) or the myc nucleoprotein (Rabbits, 1985) . The dependence of these secondary features on the high ras and myc expression can best be confirmed by use of new plasmid constructs in which oncogene expression can be modulated by extracellular agents, but the data presented here are consistent with the view that biological aggressiveness may be the result of a constellation of cellular features, engendered in different proportions by the products of different oncogenes.
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